Figure 3

Comparison of the cellular viability and the ex vivo cytotoxicity of expanded HD-NKs and PD-NKs (A-B) Representative FCM diagrams (A) and statistical analysis (B) of the percentages of apoptotic NKs in expanded HD-NKs and PD-NKs at day 14. (C-D) The representative distribution (C) and statistical analysis (D) of expanded HD-NKs and PD-NKs in the indicated sub-stages of cell cycle. (E-F) Representative FCM diagram (E) and statistical analysis (F) of CD107a⁺ expanded HD-NKs and PD-NKs in co-culturing with the indicated tumor cell lines (K562, Nalm6, U937) at the effector-to-target ratios (E: T=1:5). (G-H) Comparison of the ex vivo cytotoxicity of the expanded HD-NKs and PD-NKs against the indicated tumor cell line on the basis of BV-421⁺ cells (G) and living of tumor cells (H). All data were shown as mean ± SEM (N=3 independent experiments). NS, not significant; *, P<0.05; **, P<0.01; ***, P<0.001.